Tolgabide
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
4-{[(E)-(3-Chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 86914-11-6 |
| ATC code | none |
| PubChem | CID 5748792 |
| ChemSpider | 14917033 |
| UNII |
0L55QF645F |
| KEGG | D06181 |
| ChEMBL | CHEMBL2104937 |
| Chemical data | |
| Formula | C18H18Cl2N2O2 |
| Molar mass | 365.25 g/mol |
| |
| |
Tolgabide INN (SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.[1][2]
Synthesis

See also
References
- 1 2 David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- ↑ "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). 2002.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
